 |
 |
 |
 |
 |
 |
 |
 |
With his expert eye and trademark wit, David Wohl, M.D., takes you behind the data for an up-close look at what the numbers really mean.
More JournalViews >>
NEW! Top 10 HIV Clinical Developments of 2007
NEW! Women and HIV -- Natural History, Prevention and Treatment: CROI 2008 Highlights
NEW! Management of Treatment-Experienced Patients: CROI 2008 Highlights
NEW! Complications of HIV/HAART: CROI 2008 Highlights
NEW! First-Line HIV Therapy and Treatment Strategies: CROI 2008 Highlights
HIV specialists answer questions on:
Unusual ARV Regimen
"We have a new patient on Epivir 150 mg he takes every other day / 2 weeks on then 2 weeks off, Reyataz 150 mg every other day, Viramune 200 mg every other day and Norvir 100 mg every other day." -- David Wohl, M.D., responds
Crypto Meningitis
"My patient had a second bout of crypto and is now blind. Will the sight return when crypto is under control?" -- Ben Young, M.D., Ph.D., responds
"60 Minutes" Profiles Partners in Health Co-Founder Paul Farmer
Global Fund Might Consider Loans for Countries That Become Too Wealthy to Qualify for Grants
N.Y. Lawmakers, HIV Advocates Working to Address HIV Funds for Counties
More Women Than Men Sought Services at Uganda's AIDS Support Organization in 2007
CROI 2008 Highlights
- Women and HIV -- Natural History, Prevention and Treatment: Summary and Slides by Kathryn Anastos, M.D.
- Management of Treatment-Experienced Patients: Summary and Slides by Cal Cohen, M.D., M.S.
- Complications of HIV/HAART: Summary and Slides by David Wohl, M.D.
- First-Line HIV Therapy and Treatment Strategies: Summary and Slides by David Wohl, M.D.
- Full Coverage of CROI 2008
HIV and Me: An African American's Guide to Living With HIV
Free patient education! This easy-to-read guide from The Body is now available to download or in print.
"When to Start?" Has a New Answer
Joel Gallant, M.D., summarizes the latest changes to U.S. HIV treatment guidelines.
Abacavir, ddI Associated With Higher MI Risk
Jens Lundgren, M.D., summarizes surprising new data from the D:A:D study and discusses the ramifications of the results.
Analysis: U.S. Approval of Etravirine
Cal Cohen, M.D., M.S. summarizes the essential details of the approval of etravirine (TMC125, Intelence) and its impact.
Introducing Raltegravir
David Wohl, M.D., discusses the approval of raltegravir (MK-0518, Isentress) and its potential impact on the treatment of HIV-infected patients.
The Body PRO is a service of Body Health Resources Corporation, 250 West 57th Street, New York, NY 10107. The Body PRO and its logos are trademarks of Body Health Resources Corporation, which owns the copyright of The Body PRO's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body PRO is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body PRO should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.
© 2007 Body Health Resources Corporation